Protalix BioTherapeutics (PLX) Capital Expenditures (QoQ) (2010 - 2026)
Protalix BioTherapeutics (PLX) Capital Expenditures (QoQ) (2010 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Protalix BioTherapeutics | 190.95 Mn | 180.16 Mn | 29.62 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 187.88% |
| Dec 31, 2025 | -201.05% |
| Sep 30, 2025 | 1,848.98% |
| Jun 30, 2025 | -111.48% |
| Mar 31, 2025 | 0.47% |
| Dec 31, 2024 | -42.26% |
| Sep 30, 2024 | 3,044.00% |
| Jun 30, 2024 | -117.12% |
| Mar 31, 2024 | 151.23% |
| Dec 31, 2023 | -163.76% |
| Sep 30, 2023 | 254.76% |
| Jun 30, 2023 | -61.35% |
| Mar 31, 2023 | 625.81% |
| Dec 31, 2022 | -150.00% |
| Sep 30, 2022 | 785.71% |
| Jun 30, 2022 | -79.10% |
| Mar 31, 2022 | 107.31% |
| Dec 31, 2021 | -366.57% |
| Sep 30, 2021 | 22.42% |
| Jun 30, 2021 | -27.20% |